Literature DB >> 6519164

Pharmacokinetics of high doses of piretanide in moderate to severe renal failure.

C Marone, F C Reubi, M Perisic, W Lahn.   

Abstract

The pharmacokinetics of piretanide was studied in 10 patients with chronic renal failure. After administration of a high oral dose (12 to 192 mg) of piretanide the kinetics behaved according to an open 2-compartment model. The elimination constant in the first phase (alpha) ranged from 0.385 to 0.756 h-1 and in the second phase (beta) from 0.079 to 0.274 h-1. The corresponding elimination half-lives ranged from 55 to 108 min (t 1/2 alpha) and from 152 to 524 min (t 1/2 beta). Only an average of 2.8% of the orally administered drug was recovered in 24 h urines. Nevertheless, a good correlation was found between urinary recovery or renal clearance of the drug and residual renal function. The elimination of piretanide by non-renal mechanisms appeared to be increased when renal function was greatly diminished.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6519164     DOI: 10.1007/bf00556897

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Elimination of furosemide in healthy subjects and in those with renal failure.

Authors:  B Beermann; E Dalén; B Lindström
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

3.  Pharmacokinetics of furosemide in advanced renal failure.

Authors:  C M Huang; A J Atkinson; M Levin; N W Levin; A Quintanilla
Journal:  Clin Pharmacol Ther       Date:  1974-10       Impact factor: 6.875

4.  Pharmacokinetics of furosemide in normal subjects and functionally anephric patients.

Authors:  R E Cutler; A W Forrey; T G Christopher; B M Kimpel
Journal:  Clin Pharmacol Ther       Date:  1974-06       Impact factor: 6.875

5.  Comparison of the short-term effects of the loop diuretic piretanide and furosemide in patients with renal insufficiency.

Authors:  C Marone; F C Reubi; W Lahn
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Kinetics of a high dose of piretanide in renal failure.

Authors:  J L Brazier; N Pozet; G Faucon; J Traeger; A Hadj-Haissa
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Kinetic and dynamic comparison of piretanide and furosemide.

Authors:  J R Lawrence; A F Ansari; H L Elliott; D J Sumner; G F Brunton; B Whiting; R Whitesmith
Journal:  Clin Pharmacol Ther       Date:  1978-05       Impact factor: 6.875

8.  A radioimmunoassay to measure piretanide in human serum and urine.

Authors:  W Heptner; S Baudner; E E Dagrosa; C Hellstern; R Irmisch; H Strecker; H Wissmann
Journal:  J Immunoassay       Date:  1984

9.  Effects of a new diuretic (piretanide) compared with furosemide on renal diluting and concentrating mechanisms in patients with the nephrotic syndrome.

Authors:  C Marone; F C Reubi
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

10.  The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease.

Authors:  L A Marcantonio; W H Auld; W R Murdoch; R Purohit; G G Skellern; C A Howes
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

View more
  4 in total

1.  Pitfalls of pharmacokinetic dosage guidelines in renal insufficiency.

Authors:  K Turnheim
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of some newer diuretics.

Authors:  B Beermann; M Grind
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

Review 3.  The efficacy of diuretics in acute and chronic renal failure. Focus on torasemide.

Authors:  T Risler; B Krämer; G A Müller
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 4.  Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.